CRISPR Therapeutics CRSP Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax?
- CRISPR Therapeutics (CRSP) reported other comprehensive income unrealized holding gain loss on securities arising during period net of tax of -$6.73M in Q1 2026.
- How has CRISPR Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax changed year-over-year?
- CRISPR Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax decreased by 398.6% year-over-year, from $2.25M to -$6.73M.
- What is the long-term trend for CRISPR Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax?
- Over 3 years (2021 to 2025), CRISPR Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax has grown at a -15.0% compound annual growth rate (CAGR), from -$4.97M to $3.05M.
- What does other comprehensive income unrealized holding gain loss on securities arising during period net of tax mean?
- This measures the change in the fair value of investment securities held by the company that have not yet been sold. It reflects the market-driven appreciation or depreciation of the company's investment portfolio. This metric provides insight into the performance of the company's treasury management and non-core financial assets.